At what enterprise value was SCHÜLKE acquired in 2023?

You can find the full valuation details of SCHÜLKE on mynth capital. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of SCHÜLKE when it was acquired by ATHOS CONSORTIUM?

The estimated EV/EBITDA multiple for SCHÜLKE is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was SCHÜLKE acquired by ATHOS CONSORTIUM?

SCHÜLKE was acquired by ATHOS CONSORTIUM in 2023.

What was the EBITDA of SCHÜLKE during the acquisition?

SCHÜLKE's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the SCHÜLKE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SCHÜLKE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://eqtgroup.com/news/eqt-private-equity-to-sell-schulke-a-sustainability-leader-in-infection-prevention-and-treatment-for-the-healthcare-industry-2023-08-07

← DATABASE

Home Database Healthcare & PharmaSCHÜLKE

08/2023

SCHÜLKE acquired by ATHOS CONSORTIUM

GERMANY Life Sciences / Medical Devices / Medical Consumables EV 1b - 4b EUR

Context

EQT Private Equity has agreed to sell 100% of Schülke to a consortium led by ATHOS, following a highly successful three-year transformation period. EQT originally acquired the company in a 2020 carve-out from Air Liquide for approximately €1.0 billion. During its ownership, EQT repositioned Schülke as a pure-play healthcare leader, executing five add-on acquisitions and divesting the personal care division. This strategic focus resulted in double-digit annual revenue growth and a near doubling of EBITDA in the core healthcare segment. The sale to the ATHOS Consortium represents a transition from institutional private equity to long-term family office ownership, aligning with Schülke’s 135-year heritage and its mission to protect lives worldwide.

In the past, SchüLke underwent an LBO led by Eqt Partners in 2020.

SCHÜLKE, which reported an EBITDA margin of LOGIN in 2023, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1889, Schülke is a global leader in infection prevention and treatment solutions for the healthcare and life sciences industries. Headquartered in Norderstedt, the company specializes in high-quality disinfectants, antisepsis products, and wound care solutions, featuring iconic brands such as octenisept, kodan, and desderman. Its business model focuses on mission-critical hygiene for hospitals, pharmacies, and direct patient care channels. Under recent private equity ownership, the company underwent a major strategic repositioning to exit non-core personal care segments and focus entirely on healthcare. Schülke operates three production sites in Germany, France, and Brazil, and maintains market-leading positions in Central and Eastern Europe, Australia, and Brazil.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Other operations with SCHÜLKE

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
09/2020	EQT PARTNERS	SCHÜLKE	GERMANY	Life Sciences	EQT completed the acquisition of 100% of Schülke from its parent company, Air Liquide. This transaction represents a strategic carve-out for Air Liquide, allowing the French industrial gas giant to refocus on its core activities while providing Schülke with the independent capital necessary for long-term expansion

REFERENCES

Valuation range: EV 1b - 4b EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SCHÜLKE by ATHOS CONSORTIUM are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: schülke